Clinical Trials

201604029

NRG-GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or…

201704028

A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cervical Cancer

201710005

NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer. Phase II/III Principal Investigator…

201804136

Does antibiotic prophylaxis reduce wound complications after vulvar excision of premalignant lesions: A Double-Blinded Randomized Controlled Trial Phase II (Cancer Prevention) Principal Investigator Mullen, Mary Disease Site No Disease Learn more about this study at:…

201806120

Ovation II: Protocol 201-17-201: A Phase I/II study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly…

201807008

A Phase IB Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, to Patients With Advanced Platinum-Sensitive Ovarian Cancer (YO40482) Phase I Principal Investigator Mutch, David Disease Site Other Female Genital; Ovary;…

201809090

AVB500-OC-002: A PHASE 1B/2 RANDOMIZED, CONTROLLED STUDY OF AVB-S6-500 IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN OR PACLITAXEL IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER

201811104

Stand up to Cancer: WISP Trial (Women Choosing Surgical Prevention) Phase II (Cancer Prevention) Principal Investigator Hagemann, Andrea Disease Site Other Female Genital; Ovary Learn more about this study at: clinicaltrials.gov

201907060

A Phase I Study of PD-1 Inhibition with TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer Phase I Principal Investigator Markovina, Stephanie Disease Site Other Female Genital Learn more about…

201908011

GOG 3031: [TESARO 4010-03-001] A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) Phase III Principal Investigator Powell,…

201909052

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC# 776864) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

201909083

A Phase I A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours Phase I (Cancer Control) Principal Investigator Devarakonda, Siddhartha Disease Site Anus; Breast; Colon; Esophagus; Kidney; Liver; Lung; Lung…

201910084

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)(KEYLYNK-001 / ENGOT-ov43) Phase III…

201910142

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Phase III Principal Investigator Thaker, Premal Disease Site Ovary…

201910148

A Phase 2, Single Arm Study of Atezolizumab + Bevacizumab in women with advanced, recurrent or persistent endometrial cancer Phase II (Cancer Control) (Cancer Prevention) Principal Investigator McCourt, Carolyn Disease Site Corpus Uteri Learn more…

201912015

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy Phase…

202001099

A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer Phase II Principal Investigator Mutch, David Disease Site Other Female Genital; Ovary Learn more about this study at: clinicaltrials.gov

202002046

ENGOT-ov50 / INNOVATE-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer Phase III (Cancer Control) Principal Investigator Thaker, Premal Disease Site Cervix;…

202003113

A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Phase III Principal Investigator Thaker, Premal Disease Site Corpus Uteri;…

202004223

MS200647_0017: A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing Chemotherapy Phase II Principal Investigator Mutch, David Disease…

202004237

De-escalated Conformal Radiation Expedited Sequentially with Chemotherapy for Endometrial Cancer (DeCRESCEndo) Phase N/A Principal Investigator Lin, Alexander Disease Site Corpus Uteri Learn more about this study at: clinicaltrials.gov

202005122

O